CAR-T therapy remains poorly effective in glioblastoma (GBM) due to the tumor’s high antigen heterogeneity and immunosuppressive microenvironment. This study reports a multimodal platform for GBM immunotherapy that combines dual-antigen oncolytic viruses with bispecific CAR-T (BiCAR-T) and CAR-NK cells.
- Jia Li
- Shyambabu Chaurasiya
- Yanhong Shi
